CN1524447A - Antioxidant compositions - Google Patents
Antioxidant compositions Download PDFInfo
- Publication number
- CN1524447A CN1524447A CNA031263607A CN03126360A CN1524447A CN 1524447 A CN1524447 A CN 1524447A CN A031263607 A CNA031263607 A CN A031263607A CN 03126360 A CN03126360 A CN 03126360A CN 1524447 A CN1524447 A CN 1524447A
- Authority
- CN
- China
- Prior art keywords
- vitamin
- alpha
- lipoic acid
- oxidant compositions
- excipient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003963 antioxidant agent Substances 0.000 title claims description 24
- 230000003078 antioxidant effect Effects 0.000 title claims description 24
- 239000000203 mixture Substances 0.000 title claims description 18
- AGBQKNBQESQNJD-UHFFFAOYSA-N lipoic acid Chemical compound OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 claims description 58
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 52
- 235000019136 lipoic acid Nutrition 0.000 claims description 29
- 229960002663 thioctic acid Drugs 0.000 claims description 29
- 229930003427 Vitamin E Natural products 0.000 claims description 26
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 26
- 229940046009 vitamin E Drugs 0.000 claims description 26
- 235000019165 vitamin E Nutrition 0.000 claims description 26
- 239000011709 vitamin E Substances 0.000 claims description 26
- 235000006708 antioxidants Nutrition 0.000 claims description 23
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 4
- 229920002472 Starch Polymers 0.000 claims description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 4
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 4
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 4
- 239000008107 starch Substances 0.000 claims description 4
- 235000019698 starch Nutrition 0.000 claims description 4
- 235000013402 health food Nutrition 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 239000007937 lozenge Substances 0.000 claims description 2
- 229920000609 methyl cellulose Polymers 0.000 claims description 2
- 239000001923 methylcellulose Substances 0.000 claims description 2
- 235000010981 methylcellulose Nutrition 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 239000002994 raw material Substances 0.000 claims 3
- 241000700159 Rattus Species 0.000 description 12
- 230000000694 effects Effects 0.000 description 10
- 210000002966 serum Anatomy 0.000 description 10
- 230000003064 anti-oxidating effect Effects 0.000 description 9
- 150000003254 radicals Chemical class 0.000 description 9
- 206010039966 Senile dementia Diseases 0.000 description 8
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- 102000019197 Superoxide Dismutase Human genes 0.000 description 6
- 108010012715 Superoxide dismutase Proteins 0.000 description 6
- 230000002265 prevention Effects 0.000 description 6
- IZFHEQBZOYJLPK-SSDOTTSWSA-N (R)-dihydrolipoic acid Chemical compound OC(=O)CCCC[C@@H](S)CCS IZFHEQBZOYJLPK-SSDOTTSWSA-N 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 208000024827 Alzheimer disease Diseases 0.000 description 4
- 208000024172 Cardiovascular disease Diseases 0.000 description 4
- 208000002177 Cataract Diseases 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 208000026106 cerebrovascular disease Diseases 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 4
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 3
- 229930003268 Vitamin C Natural products 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 230000002526 effect on cardiovascular system Effects 0.000 description 3
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 235000019154 vitamin C Nutrition 0.000 description 3
- 239000011718 vitamin C Substances 0.000 description 3
- 206010029240 Neuritis Diseases 0.000 description 2
- 206010036105 Polyneuropathy Diseases 0.000 description 2
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 239000010408 film Substances 0.000 description 2
- 235000003969 glutathione Nutrition 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000003859 lipid peroxidation Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 238000005502 peroxidation Methods 0.000 description 2
- -1 peroxynitric acid salt free radical Chemical class 0.000 description 2
- 208000019629 polyneuritis Diseases 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 1
- 208000027219 Deficiency disease Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 206010027439 Metal poisoning Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- DCTLJGWMHPGCOS-UHFFFAOYSA-N Osajin Chemical compound C1=2C=CC(C)(C)OC=2C(CC=C(C)C)=C(O)C(C2=O)=C1OC=C2C1=CC=C(O)C=C1 DCTLJGWMHPGCOS-UHFFFAOYSA-N 0.000 description 1
- 208000019155 Radiation injury Diseases 0.000 description 1
- OUZCFMSJGDEXRT-UHFFFAOYSA-N Scandinone Natural products O=C1C=2C(OC)=C(CC=C(C)C)C=3OC(C)(C)C=CC=3C=2OC=C1C1=CC=C(O)C=C1 OUZCFMSJGDEXRT-UHFFFAOYSA-N 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000005030 aluminium foil Substances 0.000 description 1
- 229910052785 arsenic Inorganic materials 0.000 description 1
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229910052793 cadmium Inorganic materials 0.000 description 1
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 229940094952 green tea extract Drugs 0.000 description 1
- 235000020688 green tea extract Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000010501 heavy metal poisoning Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 238000010630 lipid peroxidation (MDA) assay Methods 0.000 description 1
- 239000012263 liquid product Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000001589 microsome Anatomy 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses an antioxidant composition comprising the constituents of alpha-thioctacid, vitamin E and excipient, wherein the antioxidant composition can be in the form of tablet, capsule, lozenge, pill, granule, or syrup, and the composition can be in the state of solid, semi-solid or liquid, the invention also discloses the use of the antioxidant composition in making health food that possesses the effects of removing free radicals, oxidation resistance, postponing senescence, beauty treatment and body-building, and the prevention of cardiovascular disease, cerebrovascular disease, malignant tumor, senile dementia and other senility diseases.
Description
Technical field:
The present invention relates to a kind of composition, especially relate to a kind of anti-oxidant, delay senility and the anti-oxidant compositions of beautification function.
Background technology:
Alpha-lipoic acid (Alpha Lipoic Acid, molecular formula: C
8H
14O
2S
2) have certain drug action and be applied to clinical existing a lot of year history, Germany in last century the seventies once its medicine as treatment hepatitis, ratify the treatment that it is used for type ii diabetes recently again.
In recent years discover alpha-lipoic acid (Alpha Lipoic Acid, molecular formula: C
8H
14O
2S
2) have an excellent antioxidation effect.Alpha-lipoic acid and the dihydrolipoic acid that forms in vivo thereof can effectively be removed hydroxy radical, peroxide radical, cross harmful substances such as hydrogen base free radical, peroxynitric acid salt free radical; can improve simultaneously the level of glutathion inside cell; impel redox and the regeneration of vitamin C in the blood, E; fat-soluble or the water-soluble free radical of deactivation; protection lipoprotein and film; prevent atherosclerotic, the generation of prevention cardiovascular and cerebrovascular diseases, malignant tumour and senile dementia, delaying human body caducity.
Modern life science studies have shown that, the free radical of the various ways that produces in the body metabolism process and peroxidating are the major reasons that causes human senility and diseases such as cardiovascular and cerebrovascular diseases, malignant tumour and senile dementia.Seek best antioxidant, delaying human body caducity prevents as far as possible and reduces disease of old people, prolongs human longevity, improves quality of life, is one of main task of new century life science.
Summary of the invention:
In order effectively to remove too much free radical in the human body, prevent and reduce the problem of human senility that peroxidation causes and cardiovascular and cerebrovascular diseases, bad habit tumour, senile dementia, the purpose of this invention is to provide a kind of anti-oxidant compositions that can effectively remove free radical in the human body.
Technical scheme of the present invention realizes in the following manner:
A kind of anti-oxidant compositions, it includes following component:
Alpha-lipoic acid
Vitamin E
Excipient
Technical scheme of the present invention can also realize in the following manner:
Alpha-lipoic acid 30-40%
Vitamin E 2-10%
Excipient 50-68%
The preferred technical solution of the present invention realizes in the following manner:
Alpha-lipoic acid 30-40%
Vitamin E 2-5%
Excipient 55-65%
Best-of-breed technology scheme of the present invention realizes in the following manner:
Alpha-lipoic acid 33.3%
Vitamin E 3.33%
Excipient 63.33%
Excipient is: starch, methylcellulose, carboxymethyl cellulose.
Above-mentioned anti-oxidant compositions is solid-state, semisolid or the liquid product made from tablet, capsule, lozenge, pill, granule, syrup form.The application of above-mentioned anti-oxidant compositions in making medicine; The application of above-mentioned anti-oxidant compositions in making health food.
Inventive point of the present invention is to utilize the potent anti-oxidation function of alpha-lipoic acid, and with the vitamin E compatibility, strengthen and improve both antioxidations in human body more.
Vitamin E (Vitamin E, molecular formula: C
31H
52O
3) be a kind of known outstanding antioxidant, can remove peroxide radical, hydrogen peroxide, but it only can work in cell membrane and lipid, in cell liquid, have only on a small quantity or not to the effect of Green Tea Extract.
Discover that alpha-lipoic acid and vitamin E have the effect of complementing each other, utilizing mutually in human body.Alpha-lipoic acid and dihydrolipoic acid (DHLA) the protection microsome that forms in vivo thereof must just work under the situation that vitamin E exists.And alpha-lipoic acid/DHLA can make vitamin E regeneration, circulation in the human body, makes it continue the anti-oxidant usefulness of performance.
Experiment shows that alpha-lipoic acid and partial oxidation in vivo also substance dihydrolipoic acid have antioxidation widely.Alpha-lipoic acid is compared its good effect with vitamin E, vitamin C with some plant osajin antioxidants:
1. both water-soluble, be dissolved in fat again; And vitamin E only is dissolved in fat, and vitamin C is only water-soluble.
2. can enter in tissue, cell and the extracellular fluid, and be evenly distributed.
3. can in water or membrane lipid structure, work.And vitamin E can only work in film or lipid conformation.
4. can bring into play antioxidation by transition metal chelate, as with Mn
2+, CU
2+, Zn
2+In the stable complex compound of generation.
5. can in human body, reduce vitamin E, C, it is circulated in vivo, improve glutathione intercellular level, bring into play its antioxidation separately, be used to prevent vitamin E, C deficiency disease.The present invention is as health food, can reach efficient removing free radical anti-oxidant, delay senility, the effect of cosmetology and health, also have the effect of prevention cardiovascular disease, cerebrovascular disease, malignant tumour, senile dementia and other disease of old people.
The present invention is based on alpha-lipoic acid, add appropriate vitamin E, middle-aged and old vitamin E insufficiency of intakes that often have have been remedied, alpha-lipoic acid is to the defective of hydrogen peroxide and peroxy radicals scavenging effect difference, each comfortable advantage of removing the anti-oxidant aspect of free radical of having brought into play both, make antioxidation of the present invention more comprehensively, more effective.
The specific embodiment: the invention will be further described below in conjunction with embodiment:
Embodiment one:
Alpha-lipoic acid 30%
Vitamin E 10%
Starch 60%
The technological process of production by above-mentioned prescription aluminium foil carton packaging product is as follows:
Production operation process and process conditions
Embodiment two:
Alpha-lipoic acid 35%
Vitamin E 5%
Excipient 60%
Preparation technology is with embodiment one.
Embodiment three
Alpha-lipoic acid 30%
Vitamin E 2-10%
Starch+carboxymethyl cellulose 68%
The tablet thin film coating production and processing technology of above-mentioned prescription is
Embodiment four:
Alpha-lipoic acid 40%
Vitamin E 10%
Carboxymethyl cellulose 50%
Preparation technology is with embodiment three.
The present invention has tangible antioxidation through the zoopery proof, and its experimental procedure and result are as follows:
1. the antioxidation of SD rat is tested.
Select 65 of SD rats for use, wherein 52 is aged mouse of 12 monthly ages, and 13 is mouse in few age at 3 monthly ages, average every body weight 350g.Be divided into 5 groups, 13 every group, all measured the content of MDA (MDA) in the rat blood serum before the test, and according to its content random packet.Being subjected to examination to organize 3 groups, is the feeding rat by the present invention's recommend to be grown up 5 times, 10 times, 20 times of consumption 900mg (including alpha-lipoic acid 300mg, vitamin E 30mg) respectively, and each organizes dosage is 25mg/d/ days, 50mg/d/ days, and 100mg/d/ days.Add 100ml distilled water, per os is irritated and is fed (1ml/100gbw).
If two control groups, cohort and few age (monthly age) are organized each one, use with method to be compared with capacity distilled water.
5 groups of edible same qualified full nutrition feeds.
Give rat continuously and tried thing after 60 days, adopt tail blood earlier, separation of serum is made the vigor of Content of MDA and superoxide dismutase (SOD); Put to death then, get liver, preparation 5% LH, carry out the MDA assay.The result shows:
The present invention can obviously reduce the MDA content in the old rats serum.MDA in the serum (MDA) is one of dead end product of biological cell membrane lipid peroxidation, measures its content, can estimate the effect of the present invention to lipid peroxidation indirectly.
As shown in table 1:
Table 1: the present invention is to the influence of old rats serum MDA
Divide (mg/kg) serum MDA (nmol/ml)
25 11.47±1.62
50 10.50±1.15
100 9.20±1.45
Control group 14.98 ± 3.98 of the same age
Lack control group 9.1042.04 in age
Be subjected to examination organize 3 groups with control group serum of the same age in MDA content relatively, obvious minimizing is all arranged, have significant difference (P＜0.01).
The present invention can significantly improve the vigor of SOD in the old rats serum.
SOD can catalysis ultra-oxygen anion free radical (O
2) generation H
2O
2, remove O by chemical reaction
2The toxic action of pair cell.As shown in table 2.
Table 2: the present invention is to the influence of old rats SOD in serum
Grouping (mg/kg) SOD in serum (NU/ml)
25 410.9±49.6
50 434.2±46.2
100 463.2±41.5
Control group 367.2 ± 60.7 of the same age
Few age, control group 472.9 ± 79.0
Tried 3 groups and compared with aged control group, P＜0.05, difference has remarkable meaning.
The present invention has the effect of the MDA in the remarkable reduction rat liver, and is as shown in table 3.
Table 3: the present invention is to the influence of old rats liver MDA
Grouping (mg/kg) 5% LH MDA (nmol/mgprot)
25 1.18±0.31
50 1.14±0.30
100 1.10±0.31
Control group 1.47 ± 0.51 of the same age
Few age, control group 1.09 ± 0.33
Tried 3 groups and compared difference significance (P＜0.05) with control group of the same age.
Each dosage group rat body weight is compared with control group of the same age slightly and is weighed before and after the experiment, but does not have significant difference (P＞0.05).
The present invention can obviously prolong mouse life.
The selection standard experiment mice, 40, each 20 of ♂, ♀ were for 3 monthly ages, and 10 is 1 group, all gives the standard particle feed.The A group is control feed control group; The B group is organized for the present invention is subjected to examination, and consumption is pressed 150mg/kg/ day and calculated, and irritates with per os behind the distilled water diluting and feeds, and carries out observing continuously life cycle.As a result, be subjected to examination group mouse mean survival time (MST) increase by 138.5 days, increase by 195 days maximum life cycle.As shown in table 4.
Table 4: the present invention is to prolonging the effect of mouse life
Group sex example countless mean survival time (MST) (my god) the highest life cycle
A control feed ♂ 10 551 ± 25 710
♀ 10 542±33 721
B controls feed+♂ 10 688 of the present invention ± 27 896
♀ 10 682±27 916
P＜0.01 has significant difference.
The present invention also has following effect except that having above high-efficiency antioxidant effect:
1. the supplemental treatment type ii diabetes improves islet function and glucose metabolism.It can make the burning utilization of glucose increase, thereby reduces blood sugar; Simultaneously can also improve diabetic's glycemic control, reduce and use insulin or hypoglycemic medicine.Germany's approved alpha-lipoic acid is used for the treatment of diabetes.
2. neuroprotective cell, the complication polyneuritis of assisting in preventing and treating type ii diabetes can make diabetic's DPN alleviate, and the person has the prevention protective effect to the nervous symptoms not occurring as yet.Suffer from the polyneuritis patient through 120 routine type ii diabetes people and volunteer to try out, take 800mg (by A-LA) for each person every day, observe after 36 days, group symptom on probation is obviously improved, and patient's pain reduces by 36 points, and the placebo group only reduces by 6 points.
3. prevention cataract.Cataract is to cause owing to the crystal in the eyes is subjected to the free radical peroxidation, uses the present invention can effectively remove free radical, and the prevention cataract comprises the cataract that the prevention diabetes are caused.
4. treatment nuclear radiation injury (the medicinal report of the relevant alpha-lipoic acid of the United States, Russia).
5. treat arsenic, cadmium, mercury and other heavy metal poisoning (the medicinal report of U.S., the relevant alpha-lipoic acid of moral).
6. remove human motion (work) back muscle endoperoxide, the acceleration muscle recovery helps the sportsman and the physical labourer removes fatigue, regains one's strength.
7. improve AIDS patient's blood status, improve the T4/T8 percentage of lymphocyte, suppress HIV.
Claims (8)
1, a kind of anti-oxidant compositions, it includes following component:
Alpha-lipoic acid
Vitamin E
Excipient
2, anti-oxidant compositions according to claim 1 is characterized in that: it is formulated with following raw material:
Alpha-lipoic acid 30-40%
Vitamin E 2-10%
Excipient 50-68%
3, anti-oxidant compositions according to claim 2 is characterized in that: it is formulated with following raw material:
Alpha-lipoic acid 30-40%
Vitamin E 2-5%
Excipient 55-65%
4, anti-oxidant compositions according to claim 3 is characterized in that: it is formulated with following raw material:
Alpha-lipoic acid 33.3%
Vitamin E 3.33%
Excipient 63.33%
5, according to the described arbitrary anti-oxidant compositions of claim 1-4, it is characterized in that: excipient is: starch, methylcellulose, carboxymethyl cellulose.
6, anti-oxidant compositions according to claim 5 is characterized in that: above-mentioned anti-oxidant compositions is solid-state, semisolid or the liquid form product made from tablet, capsule, lozenge, pill, granule, syrup form.
7, the application of anti-oxidant compositions in the preparation medicine.
8, the application of anti-oxidant compositions in the preparation health food.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA031263607A CN1524447A (en) | 2003-09-16 | 2003-09-16 | Antioxidant compositions |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA031263607A CN1524447A (en) | 2003-09-16 | 2003-09-16 | Antioxidant compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1524447A true CN1524447A (en) | 2004-09-01 |
Family
ID=34285954
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA031263607A Pending CN1524447A (en) | 2003-09-16 | 2003-09-16 | Antioxidant compositions |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1524447A (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1853626B (en) * | 2005-04-29 | 2010-10-06 | 上海医药工业研究院 | Zinc sulfate freeze-dried preparation for injection |
| CN101045048B (en) * | 2006-03-27 | 2011-05-18 | 中国科学院上海生命科学研究院 | Application of chondriosome nutrient composition |
| CN103479807A (en) * | 2013-09-29 | 2014-01-01 | 四川大学华西医院 | Composition for brain protection and preparation method and application thereof |
| CN104082363A (en) * | 2014-06-11 | 2014-10-08 | 南通昊友食品添加剂有限公司 | Antioxidant for baked food |
| CN104082636A (en) * | 2014-06-11 | 2014-10-08 | 南通昊友食品添加剂有限公司 | Antioxidant composition |
| CN111035012A (en) * | 2019-12-16 | 2020-04-21 | 青岛赛珥生物医学科技有限公司 | Antioxidant nutrition combination capsule and preparation method thereof |
| CN112641091A (en) * | 2020-11-25 | 2021-04-13 | 北京斯利安药业有限公司 | Composite antioxidant containing folic acid |
-
2003
- 2003-09-16 CN CNA031263607A patent/CN1524447A/en active Pending
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1853626B (en) * | 2005-04-29 | 2010-10-06 | 上海医药工业研究院 | Zinc sulfate freeze-dried preparation for injection |
| CN101045048B (en) * | 2006-03-27 | 2011-05-18 | 中国科学院上海生命科学研究院 | Application of chondriosome nutrient composition |
| CN103479807A (en) * | 2013-09-29 | 2014-01-01 | 四川大学华西医院 | Composition for brain protection and preparation method and application thereof |
| CN104082363A (en) * | 2014-06-11 | 2014-10-08 | 南通昊友食品添加剂有限公司 | Antioxidant for baked food |
| CN104082636A (en) * | 2014-06-11 | 2014-10-08 | 南通昊友食品添加剂有限公司 | Antioxidant composition |
| CN111035012A (en) * | 2019-12-16 | 2020-04-21 | 青岛赛珥生物医学科技有限公司 | Antioxidant nutrition combination capsule and preparation method thereof |
| CN112641091A (en) * | 2020-11-25 | 2021-04-13 | 北京斯利安药业有限公司 | Composite antioxidant containing folic acid |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1268351C (en) | Sugar absorption inhibitors and process for producing the same | |
| CN1522144A (en) | Compositions for preventing human cancer and method of preventing human cancer | |
| CN1194703C (en) | Health-care food for protecting gastric mucosa and its preparing process | |
| CN1524447A (en) | Antioxidant compositions | |
| CN1253159C (en) | Health product of compound propolis and preparing method | |
| CN1204238C (en) | Kenrel oil composite extracted from plant kernel and its extraction process and application | |
| CN1241562C (en) | Application of forsythin in the process for preparing adiposis treating oral medicine and healthy food | |
| CN1166302C (en) | Mixed plant oil containing linolenic acid | |
| CN1857348A (en) | Water soluble Chinese angelica extract and its injection and their preparing process | |
| CN1864545A (en) | Preparation of highland barley SOD an conditioning food containing highland barley SOD | |
| CN1616060A (en) | A traditional Chinese medicine dripping pill preparation for promoting blood circulation and removing stasis, promoting qi and relieving pain | |
| CN1843406A (en) | Drug for reducing blood fat and preparation method thereof | |
| CN1209978C (en) | Nutritive health-care food for supplementing nucleic acid and its preparing process | |
| CN1108111C (en) | Hypolipemic rice-flour noodles and its preparing process | |
| CN1679609A (en) | Compound energy mistura fat-soluble vitamins adult preparation and use thereof | |
| CN1282422C (en) | Soft-shelled soft-shelled turtle quality improver and its application | |
| CN1190394C (en) | Pineapplie leaf extract, its preparation method and application | |
| CN1232283C (en) | Chinese drugs for treatment of coronary heart disease and angina pectoris | |
| CN1846707A (en) | Compound nutrient for raising body's hypoxia tolerance | |
| CN1247211C (en) | Health-care or medicinal tablet containing active ganoderma extract | |
| CN1249224C (en) | Superoxide dismutase composition and preparation method thereof | |
| CN1498626A (en) | Application of hyaluronic acid in raising immunity of human body and improving symptom of lacking immunity | |
| CN1730040A (en) | Buckwheat compound for treating hyperglycemia and method for producing same | |
| CN1742783A (en) | Natural medicine preparatino for tonifying Qi strengthening body resistance and preparing method | |
| CN1314405C (en) | Method for applying complete puncturevine herb in preparing medicine for treating insulin resisting hyperglycemia and hypertension |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |